NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
NexGel, Inc. NXGL
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$11.4M
▲ 31.5% vs FY2024
EPS · FY25
$-0.38
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-58.7%
Net margin · FY25
-26.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 11.4M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 26 cents on every revenue dollar this year.
Per share
USD -0.38
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-58.7%
Return on equity, FY2025
ROE
Operating margin-29.3%
Net margin-26.3%
Return on assets-28.0%
Each USD of equity lost 59 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+76.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+77.3%
+76.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 10.5M
total assets, end of FY2025
Total assetsUSD 10.5M
EquityUSD 4.5M
Gross debtUSD 588,000.00
Current ratio1.47×
Equity funds 43% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.38
−0.50
−0.56
−0.85
−1.45
−1.05
−0.14
−0.38
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−58.7
−62.8
−51.2
−48.1
−70.9
−1004.0
−581.8
−671.9
Shares out B
0.01
0.01
0.01
0.01
0.01
0.00
0.06
0.06
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
32 of 32
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed